NVSEF - AbbVie immunology chief to lead Novartis commercial operations
2023-09-06 10:21:15 ET
More on AbbVie, Novartis, etc.
- AbbVie: Proving The Bears Wrong Again As Shares Surged
- AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued
- AbbVie: Balance Is Everything
- AbbVie: Still A Buy According To Buffett's 10xEBT Rule
- AbbVie Inc. 2023 Q2 - Results - Earnings Call Presentation
- Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?
- Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors
- Novartis: Q2 Beats Expectations, But Still Pricey
- Why is big pharma unmoved despite Medicare pricing threat?
- Republicans say Medicare drug negotiations will mean fewer new meds
- AbbVie seeks US, EU approval for Skyrizi for ulcerative colitis
- Wall Street lists potential targets for Medicare drug price negotiations
- Crohn's disease drugmakers set to benefit from expected rise in cases
- Novartis ending development of pancreatic cancer asset licensed from XOMA
- FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri
For further details see:
AbbVie immunology chief to lead Novartis commercial operations